Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–6 of 6 results
Advanced filters: Author: Richard B. Lanman Clear advanced filters

  • Circulating tumour DNA can provide useful information on disease burden. Here, the authors analysed circulating tumour DNA from 800 patients from a breast cancer clinical trial and investigate the subclonal nature of the disease, and identify DNA mutations associated with resistance and poor survival.

    • Belinda Kingston
    • Rosalind J. Cutts
    • Nicholas C. Turner
    ResearchOpen Access
    Nature Communications
    Volume: 12, P: 1-12

  • Era+ breast cancer patients often develop resistance to endocrine therapy. Here, the authors show that FGFR1 amplification is a resistance mechanism to CDK4/6 inhibitor and endocrine therapy and that combined treatment with FGFR, CDK4/6, and anti-estrogens is a potential therapeutic strategy in Era+ breast cancer tumors.

    • Luigi Formisano
    • Yao Lu
    • Carlos L. Arteaga
    ResearchOpen Access
    Nature Communications
    Volume: 10, P: 1-14

  • Analysis of a large cohort of EGFR-mutant lung cancer cell-free DNA samples along with longitudinal samples from a patient with EGFR-mutant lung cancer identifies pathways that inhibit EGFR-inhibitor response. Co-occurring genetic alterations influence clinical outcomes and underscore the need for combination therapies.

    • Collin M Blakely
    • Thomas B K Watkins
    • Trever G Bivona
    Research
    Nature Genetics
    Volume: 49, P: 1693-1704

  • A subset of patients treated with selective TRK inhibitors (including the newly approved larotrectinib) develop off-target resistance mediated by genomic acquisition of MAPK pathway-activating alterations, and may benefit from combined targeted therapy.

    • Emiliano Cocco
    • Alison M. Schram
    • Maurizio Scaltriti
    Research
    Nature Medicine
    Volume: 25, P: 1422-1427